Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD

Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD

Alzheimer’s disease (AD) impacts millions of individuals worldwide. Since no cure is currently available, acetylcholinesterase inhibitors are symptomatic therapy. This study assessed community pharmacists’ knowledge regarding donepezil adverse effects (AEs) and self-care recommendations for insomnia...

Full description

Bibliographic Details
Main Authors:	Marketa Marvanova, Paul Jacob Henkel
Format:	Article
Language:	English
Published:	MDPI AG 2017-07-01
Series:	Pharmacy
Subjects:	community pharmacist pharmaceutical care Alzheimer’s disease cognitive enhancer acetylcholinesterase inhibitor donepezil rivastigmine anticholinergic agent
Online Access:	https://www.mdpi.com/2226-4787/5/3/42

Similar Items

The Effects of Donepezil, Galantamine, Rivastigmine and Memantine on Mini-Mental State Examination and Mean Flow Velocity in Patients with Vascular Dementia: A Double-Blinded Randomized Clinical Trial
by: Farhad Iranmanesh, et al.
Published: (2020-03-01)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
by: Dan-Dan Li, et al.
Published: (2019-05-01)

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model
by: M Bond, et al.
Published: (2012-04-01)

Donepezil Regulates LPS and Aβ-Stimulated Neuroinflammation through MAPK/NLRP3 Inflammasome/STAT3 Signaling
by: Jieun Kim, et al.
Published: (2021-09-01)

Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase
by: Tsuyoshi Sato, et al.
Published: (2015-09-01)

Evaluation of the Adverse Effects of Chronic Exposure to Donepezil (An Acetylcholinesterase Inhibitor) in Adult Zebrafish by Behavioral and Biochemical Assessments
by: Gilbert Audira, et al.
Published: (2020-09-01)

Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation
by: Magdalena Markowicz-Piasecka, et al.
Published: (2018-01-01)

Are there links between Alzheimer’s disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: a systematic review
by: Ramin Abdi Dezfouli, et al.
Published: (2024-02-01)

The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
by: Osman Korucu, et al.
Published: (2018-01-01)

Electrocardiographic Effects of Cholinesterase Inhibitors in Patients with Alzheimer’s Disease
by: Ayşe ÇOLAK, et al.
Published: (2022-12-01)

Improvement in delirium and visuospatial function after rivastigmine in antimuscarinic toxicity: a case report
by: Matthew S. Correia, et al.
Published: (2023-12-01)

Synthesis of New Indole Derivatives Structurally Related to Donepezil and Their Biological Evaluation as Acetylcholinesterase Inhibitors
by: Samar I. Faggal, et al.
Published: (2012-04-01)

Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model
by: Faez Saleh Al-Hamed, et al.
Published: (2020-09-01)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
by: Débora Nunes, et al.
Published: (2022-10-01)

What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink
by: Venexia M. Walker, et al.
Published: (2018-05-01)

Profiling donepezil template into multipotent hybrids with antioxidant properties
by: Eva Mezeiova, et al.
Published: (2018-01-01)

Recent developments in the design and synthesis of benzylpyridinium salts: Mimicking donepezil hydrochloride in the treatment of Alzheimer’s disease
by: Saghi Sepehri, et al.
Published: (2022-09-01)

Alzheimer’s disease: clinical management errors
by: V. A. Parfenov
Published: (2020-12-01)

Use of donepezil for neurocognitive recovery after brain injury in adult and pediatric populations: a scoping review
by: Avery L Miller, et al.
Published: (2024-01-01)

Development of novel salicylic acid–donepezil–rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease
by: Yi Zhou, et al.
Published: (2023-12-01)

The effects of novel 7-MEOTA-donepezil like hybrids and N-alkylated tacrine analogues in the treatment of quinuclidinyl benzilate-induced behavioural deficits in rats performing the multiple T-maze test
by: Jan Misik, et al.
Published: (2015-12-01)

First Synthesis of Racemic <i>Trans</i> Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer’s Disease
by: Benjamin Guieu, et al.
Published: (2020-12-01)

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients
by: Zhang N, et al.
Published: (2018-10-01)

Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
by: Marwan Sabbagh, et al.
Published: (2016-09-01)

EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE
by: R. Abolfazli, et al.
Published: (2008-04-01)

Clinical Assessment of Alzheimer’s Disease and Response to Donepezil Treatment
by: Serge Gauthier
Published: (2020-12-01)

Kinetic and structural studies on the interactions of Torpedo californica acetylcholinesterase with two donepezil-like rigid analogues
by: Rosanna Caliandro, et al.
Published: (2018-01-01)

Differential Effects of Acetylcholinesterase Inhibitors on Clinical Responses and Cerebral Blood Flow Changes in Patients with Alzheimer's Disease: A 12-Month, Randomized, and Open-Label Trial
by: Soichiro Shimizu, et al.
Published: (2015-04-01)

Maintaining Vitality: Pharmacists’ Continuing Professional Education Decision-Making in the Upper Midwest
by: Paul Jacob Henkel, et al.
Published: (2018-02-01)

Alzheimer's disease - a review of medicinal substances and their derivatives
by: Marika Więcek, et al.
Published: (2024-02-01)

Safety of Cholinesterase Inhibitors and NMDA Receptors Antagonists for the Treatment of Patients with Dementia
by: A. P. Pereverzev, et al.
Published: (2019-12-01)

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease
by: Gabriela Dumitrita Stanciu, et al.
Published: (2023-11-01)

Early diagnosis and treatment of Alzheimer's disease
by: V. A. Parfyonov
Published: (2015-12-01)

Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Are Irreversible Inhibitors the Future?
by: Donald E. Moss
Published: (2020-05-01)

Pharmacists’ Utilization of Information Sources Related to Community and Population Needs in the Upper Midwest and Associations with Continuing Professional Education
by: Paul Henkel, et al.
Published: (2019-08-01)

Suspected donepezil toxicity: A case report
by: Carmen Gust, et al.
Published: (2020-12-01)

Cholinesterase inhibitors for Parkinson’s disease-related visual hallucinations unresponsive to atypical antipsychotics
by: Tomasz Sobow
Published: (2007-03-01)

Musical hallucinations treated with acetylcholinesterase inhibitors
by: Jan Dirk eBlom, et al.
Published: (2015-04-01)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
by: Tariot Pierre, et al.
Published: (2012-06-01)

The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
by: Tahereh Jamshidnejad-Tosaramandani, et al.
Published: (2021-11-01)